- Announced significant milestones at its Cedar Psychiatry clinics: administering over 5,000 ketamine treatments and over 2,000 Spravato™ treatments.
- Clients receiving ketamine treatment at Novamind’s Cedar Psychiatry clinics are offered specialized therapy, pre- and post-ketamine-administration (ketamine-assisted psychotherapy).
- Cedar Psychiatry specializes in evidence-based therapeutic protocols that facilitate the integration of ketamine experiences and optimize treatment outcomes for clients.
TORONTO, ON / January 28, 2021 / Novamind Inc. (CSE:NM) (“Novamind”), a leading mental health company specialized in psychedelic medicine, is proud to announce significant milestones at its Cedar Psychiatry clinics: administering over 5,000 ketamine treatments and over 2,000 Spravato™ treatments.
Launched in 2016, Cedar Psychiatry is a leading provider of innovative, evidence-based mental health therapies in the United States.
Clients receiving ketamine treatment at Novamind’s Cedar Psychiatry clinics are offered specialized therapy, pre- and post-ketamine-administration (ketamine-assisted psychotherapy). Cedar Psychiatry specializes in evidence-based therapeutic protocols that facilitate the integration of ketamine experiences and optimize treatment outcomes for clients.
The number of ketamine treatments administered at Cedar Psychiatry clinics grew 90% from 2019 to 2020. During the same period, total Spravato™ treatments at Cedar Psychiatry clinics have grown over 400%. Spravato™ is a version of ketamine that was approved by the U.S. FDA for treatment-resistant depression (TRD) in March 2019, and for major depressive disorder (MDD) with suicidal ideation or behaviour in August 2020. Clinical research studies that supported FDA approval showed that Spravato™ can effectively benefit people with these conditions, which can be difficult to treat.
“Spravato™ requires specialized infrastructure and processes that can be difficult for small mental health practices to implement, but Cedar Psychiatry has the scale and expertise to effectively manage the challenges of offering these novel medications to our clients,” commented Dr. Reid Robison, Chief Medical Officer and Director of Novamind.
“The need for innovative mental health services has never been greater. This demand is reflected in a sharp increase in visits to our clinics, and the growing adoption by our clients of alternative mental health treatments” added Yaron Conforti, CEO and Director of Novamind.
Read More: https://agoracom.com/ir/Novamind/forums/discussion/topics/754111-novamind-reaches-major-milestones-for-ketamine-and-spravato-tm-treatments/messages/2300736#message
Tags: COMPASS PATHWAYS, CSE, Field Trip Health Ltd., MIND MEDICINE (MINDMED) INC, NUMINUS WELLNESS INC, Psyched Wellness Ltd., Psychedelic, psychedelic medicine, Revive Therapeutics, small cap stocks, stocks, tsx